Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

Acta Oncologica

Volumn 46, Issue 6, 2007, Pages 741-746

  Fjällskog, Marie Louise ^a   Hessman, Ola ^a   Eriksson, Barbro ^a   Janson, Eva Tiensuu ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CANCER INHIBITION; CANCER PATIENT; CLINICAL ARTICLE; ENDOCRINE CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PANCREAS ISLET; PANCREAS TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STAINING; STROMA; TUMOR CELL;

ANTINEOPLASTIC AGENTS; ENDOCRINE SYSTEM; ENDOCRINE SYSTEM DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREAS; PANCREATIC NEOPLASMS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 34547170883     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860601048388     Document Type: Article

References (21)

1. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with malignant endocrine pancreatic tumors. Cancer 1990;65:1883-90.
2. .Öberg K. State of the art and future prospects in the management of neuroendocrine tumor. Q J Nucl Med 2000;44:3-12.
3. Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-7.
4. Fjällskog M-L, Sundin A, Westlin J-E, .Öberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002;19:35-42.
5. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003;37:1-19.
6. Simon M-P, Pedeutour F, Sirvent N. Deregulation of the platelet-derived growth factor B-chain via fusion with collagen gene COL1A1 in dermatofibrosarcom protuberans and giant-cell fibroblastoma. Nat Genet 1997;15:95-8.
7. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
8. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-3.
9. Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene 2003;22:722-33.
10. Furuhashi M, Sjöblom T, Abramsson A, Ellingsen J, Micke P, Li H, et al. PDGF production by B16 melanoma cells leads to increased coverage of vessels and an associated increase in tumor growth rate. Cancer Res 2004;64:2725-33.
11. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34.
12. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGFR signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
13. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, et al. STI571 enhances the therapeutic index of epitholone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-87.
14. Fjällskog M-L, Lejonklou M, .Öberg K, Eriksson B, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-73.
15. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
16. Fjallskog ML, Janson ET. Treatment of endocrine pancreatic tumors. Acta Oncol 2005;44:329-38.
17. Lindahl P, Boström H, Karlsson L, Hellström M, Kalen M, Betsholtz C. Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr Top Pathol 1999;93:27-33.
18. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGFR-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003;112:1142-51.
19. Bergers G, Benjamin LE. Tumorigenesis and angiogenetic switch. Nat Rev Cancer 2003;3:401-10.
20. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
21. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is angiogenetic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52.